NorthStar Medical Radioisotopes has inked a long-term supply agreement with Curie Therapeutics for NorthStar's actinium-225 (Ac-225) therapeutic radioisotope.
Under the deal, Curie will gain priority access to NorthStar's no-carrier-added Ac-225 therapeutic radioisotope. Curie will use Ac-225 to support development of targeted radiopharmaceuticals for treating patients with solid tumors, according to the vendors.
